MX2020008115A - Glucuronilacion como una nueva modificacion postraduccional acida en anticuerpos monoclonales terapeuticos. - Google Patents

Glucuronilacion como una nueva modificacion postraduccional acida en anticuerpos monoclonales terapeuticos.

Info

Publication number
MX2020008115A
MX2020008115A MX2020008115A MX2020008115A MX2020008115A MX 2020008115 A MX2020008115 A MX 2020008115A MX 2020008115 A MX2020008115 A MX 2020008115A MX 2020008115 A MX2020008115 A MX 2020008115A MX 2020008115 A MX2020008115 A MX 2020008115A
Authority
MX
Mexico
Prior art keywords
glucuronylation
monoclonal antibodies
translational modification
therapeutic monoclonal
acidic post
Prior art date
Application number
MX2020008115A
Other languages
English (en)
Inventor
Shunhai Wang
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2020008115A publication Critical patent/MX2020008115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/2201—Streptopain (3.4.22.10)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/89—Inverse chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96413—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporcionan composiciones y métodos para identificar productos farmacológicos proteicos glucuronilados.
MX2020008115A 2018-01-31 2019-01-29 Glucuronilacion como una nueva modificacion postraduccional acida en anticuerpos monoclonales terapeuticos. MX2020008115A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862624338P 2018-01-31 2018-01-31
PCT/US2019/015549 WO2019152356A2 (en) 2018-01-31 2019-01-29 Glucuronylation as a new acidic post-translational modification on therapeutic monoclonal antibodies

Publications (1)

Publication Number Publication Date
MX2020008115A true MX2020008115A (es) 2020-09-25

Family

ID=65576657

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008115A MX2020008115A (es) 2018-01-31 2019-01-29 Glucuronilacion como una nueva modificacion postraduccional acida en anticuerpos monoclonales terapeuticos.

Country Status (16)

Country Link
US (2) US11366123B2 (es)
EP (1) EP3746472A2 (es)
JP (2) JP7301054B2 (es)
KR (1) KR20200115467A (es)
CN (1) CN112135839A (es)
AR (1) AR114569A1 (es)
AU (1) AU2019213647A1 (es)
BR (1) BR112020011797A2 (es)
CA (1) CA3084181A1 (es)
EA (1) EA202091577A1 (es)
IL (1) IL276075A (es)
MX (1) MX2020008115A (es)
SG (1) SG11202005015XA (es)
TW (2) TWI808123B (es)
WO (1) WO2019152356A2 (es)
ZA (1) ZA202003320B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
WO2019152356A2 (en) 2018-01-31 2019-08-08 Regeneron Pharmaceuticals, Inc. Glucuronylation as a new acidic post-translational modification on therapeutic monoclonal antibodies
IL303510A (en) * 2020-12-11 2023-08-01 Genentech Inc Methods for determining the relative distribution of glucuronidation, iduronidation, and galacturonidation of polypeptides
CA3226049A1 (en) * 2021-07-13 2023-01-19 Regeneron Pharmaceuticals, Inc. Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2750977A1 (en) * 2009-02-09 2010-08-12 Roche Glycart Ag Immunoglobulin glycosylation pattern analysis
US20120264155A1 (en) * 2009-10-09 2012-10-18 Symphogen A/S Multiplex Quantitation of Individual Recombinant Proteins in a Mixture by Signature Peptides and Mass Spectrometry
KR101949187B1 (ko) * 2011-07-08 2019-04-22 이엠디 밀리포어 코포레이션 일회용 생명공학적 공정용의 개선된 심층 필터
CN104704499B (zh) * 2012-06-21 2018-12-11 菲利普莫里斯生产公司 与基于网络的生物标记签名相关的系统和方法
KR102332302B1 (ko) * 2013-09-13 2021-12-01 제넨테크, 인크. 세포주에서 숙주 세포 단백질 및 재조합 폴리펩티드 생성물을 검출 및 정량화하기 위한 조성물 및 방법
US20170247458A1 (en) * 2016-01-10 2017-08-31 Sorrento Therapeutics, Inc. Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR
WO2019152356A2 (en) 2018-01-31 2019-08-08 Regeneron Pharmaceuticals, Inc. Glucuronylation as a new acidic post-translational modification on therapeutic monoclonal antibodies

Also Published As

Publication number Publication date
JP2023134463A (ja) 2023-09-27
IL276075A (en) 2020-08-31
AU2019213647A1 (en) 2020-07-23
EP3746472A2 (en) 2020-12-09
TWI808123B (zh) 2023-07-11
US20220276260A1 (en) 2022-09-01
US20190234964A1 (en) 2019-08-01
CA3084181A1 (en) 2019-08-08
CN112135839A (zh) 2020-12-25
WO2019152356A3 (en) 2019-10-17
ZA202003320B (en) 2023-10-25
KR20200115467A (ko) 2020-10-07
TW202348623A (zh) 2023-12-16
EA202091577A1 (ru) 2020-10-26
AR114569A1 (es) 2020-09-23
SG11202005015XA (en) 2020-06-29
US11366123B2 (en) 2022-06-21
BR112020011797A2 (pt) 2020-11-17
WO2019152356A2 (en) 2019-08-08
JP2021512280A (ja) 2021-05-13
TW201940884A (zh) 2019-10-16
JP7301054B2 (ja) 2023-06-30

Similar Documents

Publication Publication Date Title
MX2020001879A (es) Proteínas de fijación al antígeno que se dirigen a antígenos compartidos.
ZA202003320B (en) Glucuronylation as acidic post-translational modification on therapeutic monoclonal antibodies
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
NZ738008A (en) Tigit-binding agents and uses thereof
MX2018005720A (es) Anticuerpos pd-l1, fragmento de union al antigeno del mismo, y aplicacion medica de ello.
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
PH12019502576A1 (en) Bis-octahydrophenanthrene carboxamides and protein conjugates thereof
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
EP3880239A4 (en) THERAPEUTIC SIRPalpha ANTIBODIES
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
EP3768721A4 (en) Novel anti-ctla-4 antibody polypeptide
EP3865154A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY FAB FRAGMENT COMPLEX AT LABELED ANTI-HUMAN SITE
PH12020551716A1 (en) Anti-ror antibody constructs
MX2019011624A (es) Metodos y composiciones para la reduccion de la inmunogenicidad.
SG10201801219VA (en) Anti-HER2 Antibodies
EP3416986A4 (en) ANTIBODY PROTEIN PROTEIN AND RELATED COMPOSITIONS FOR TARGETING CANCER
MY194084A (en) Interferon beta antibodies and uses thereof
MX2021007235A (es) Tubulisinas y conjugados de proteina-tubulisina.
EP3584576A4 (en) METHOD FOR IDENTIFYING A POTENTIAL DRUG TARGET PROTEIN FOR DEVELOPING AN ANTIBODY DRUG AND METHOD FOR MANUFACTURING ANTIBODY AGAINST A TARGET PROTEIN
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
IL291284A (en) Systems and methods for expression of proteins
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
EP3768722A4 (en) Novel anti-egfr antibody polypeptide
EP3753955A4 (en) CD38 PROTEIN ANTIBODIES AND ASSOCIATED USE